Thorium-229 quantified in historical Thorium-228 capsules

被引：7

作者：

Boden, Sven ^{[1
]}

Vints, Koen ^{[1
]}

Cagno, Simone ^{[1
]}

Maertens, Dominic ^{[1
]}

Van Hecke, Karen ^{[1
]}

Cardinaels, Thomas ^{[1
,2
]}

机构：

[1] Belgian Nucl Res Ctr SCK CEN, Boeretang 200, B-2400 Mol, Belgium

[2] Katholieke Univ Leuven, Dept Chem, Celestijnenlaan 200F,POB 2404, B-3001 Heverlee, Belgium

来源：

APPLIED RADIATION AND ISOTOPES | 2017年 / 120卷

关键词：

Th-229; Th-228; Ac-227; Ra-226; Ac-225; Bi-213; In-situ gamma-ray spectroscopy; Nuclear clock; Targeted alpha therapy;

D O I：

10.1016/j.apradiso.2016.11.012

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

Thorium-229 is a valuable, but scarce, radionuclide for nuclear clock applications or targeted alpha therapy. While it is mostly produced by the decay of U-233, Th-229 can also be produced by neutron irradiation of Ra-226. At SCK center dot CEN, capsules containing mainly Th-228 (by-product of Ra-226 irradiation) were characterized to quantify the present amounts of Th-229, Th-228, Ac-227, Ra-226 with high resolution gamma spectroscopy, after a decay period of 40 years in which Th-228 has decayed, High purity Th-229 was quantified, and after recovery using radiochemical separation processes, it can be used to support ongoing research.

引用

页码：40 / 44

页数：5

共 23 条

[1] Managing the Uranium-233 Stockpile of the United States [J].

Alvarez, Robert .

SCIENCE & GLOBAL SECURITY, 2013, 21 (01) :53-69

[2]

[Anonymous], 2015 LONG RANG PLAN

[3]

Baetsle L. H. D., 1972, P INT S POW RED MADR

[4]

Canberra, 2009, GENIE 2000 SPECTROSC

[5]

Canberra, 2005, MODEL S573 ISOCS CAL

[6]

Canberra, 2010, 11917 ISOCS LABSOCS

[7]

Canberra, 2003, MODEL S506 INTERACTI

[8]

EAEC, 2014, NUCL

[9] The potential and hurdles of targeted alpha therapy - clinical trials and beyond [J].

Eigqvist, Jorgen ;

Frosts, Sofia ;

Pouget, Jean-Pierre ;

Albertsson, Per .

FRONTIERS IN ONCOLOGY, 2014, 3

[10]

Eurachem and CITAC, 2012, QUANTIFYING UNCERTAI

← 1 2 3 →